Synergistic effects of clinically achievable concentrations of 12-O-tetradecanoylphorbol-13-acetate in combination with all-trans retinoic acid, 1α,25-dihydroxyvitamin D3, and sodium butyrate on differentiation in HL-60 cells

Oncology Research

Volumn 12, Issue 9-10, 2000, Pages 419-427

  Zheng, Xi ^a   Chang, Richard L ^a   Cui, Xiao Xing ^a   Kelly, Kathleen A ^a   Shih, Weichung Joe ^b,c   Lin, Yong ^b,c   Strair, Roger ^c   Suh, Junghan ^d   Han, Zheng Tao ^e   Rabson, Arnold ^c,d   Conney, Allan H ^a,c  

^a RUTGERS UNIVERSITY   (United States)

^b UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

^c ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^d RUTGERS UNIVERSITY   (United States)

^e Henan Tumor Research Institute   (China)

Author keywords

Differentiation; Growth; Leukemia; PMA; TPA

Indexed keywords

ANTINEOPLASTIC AGENT; CALCITRIOL; CALCIUM CHANNEL STIMULATING AGENT; CARCINOGEN; DYES, REAGENTS, INDICATORS, MARKERS AND BUFFERS; INTRAVENOUS ANESTHETIC AGENT; MUTAGENIC AGENT; NITROBLUE TETRAZOLIUM; OXYBATE SODIUM; PHORBOL 13 ACETATE 12 MYRISTATE; RETINOIC ACID;

APOPTOSIS; ARTICLE; CELL CULTURE; CELL DIFFERENTIATION; CELL DIVISION; CELL STRAIN HL 60; DOSE RESPONSE; DRUG EFFECT; HUMAN; TIME;

ANESTHETICS, INTRAVENOUS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CALCITRIOL; CALCIUM CHANNEL AGONISTS; CARCINOGENS; CELL DIFFERENTIATION; CELL DIVISION; DOSE-RESPONSE RELATIONSHIP, DRUG; HL-60 CELLS; HUMANS; INDICATORS AND REAGENTS; MUTAGENS; NITROBLUE TETRAZOLIUM; SODIUM OXYBATE; TETRADECANOYLPHORBOL ACETATE; TIME FACTORS; TRETINOIN; TUMOR CELLS, CULTURED;

EID: 0011130588     PISSN: 09650407     EISSN: None     Source Type: Journal    
DOI: 10.3727/096504001108747873     Document Type: Article

References (50)

1. Huberman, E.; Callaham, M. F. Induction of terminal differentiation in human promyelocytic leukemia cells by tumor-promoting agents. Proc. Natl. Acad. Sci. USA 76:1293-1297; 1979.
2. Rovera, G.; O'Brein, T. G.; Diamond, L. Induction of differentiation in human promyelocytic leukemia cells by tumor promoters. Science 204:868-870; 1979.
3. Hass, R.; Gunji, H.; Hirano, M.; Weichselbaum, R.; Kufe, D. Phorbol ester-induced monocytic differentiation is associated with G2 delay and down-regulation of cdc25 expression. Cell Growth Differ. 4:159-166; 1993.
4. 3 synergize with 12-O-tetradecanoylphorbol-13-acetate to induce macrophage differentiation in acute promyelocytic leukemia NB4 cells. Leukemia 8:1744-1749; 1994.
5. Pegoraro, L.; Abrahm, J.; Cooper, R. A.; Levis, A.; Lange, B.; Meo, P.; Rovera, G. Differentiation of human leukemias in response to 12-O-tetradecanoylphorbol-13-acetate in vitro. Blood 55:859-862; 1980.
6. Koeffler, H. P.; Bar-Eli, M.; Territo, M. Phorbol diester-induced macrophage differentiation of leukemic blasts from patients with human myelogenous leukemia. J. Clin. Invest. 66:1101-1108; 1980.
7. Han, Z. T.; Zhu, X. X.; Yang, R. Y.; Sun, J. Z.; Tian, G. F.; Liu, X. J.; Cao, G. S.; Newmark, H. L.; Conney, A. H.; Chang, R. L. Effect of intravenous infusions of 12-O-tetradecanoylphorbol-13-acetate (TPA) in patients with myelocytic leukemia: Preliminary studies on therapeutic efficacy and toxicity. Proc. Natl. Acad. Sci. USA 95:5357-5361; 1998.
8. Zylber-Katz, E.; Knode, M. C.; Glazer, R. I. Retinoic acid promotes phorbol ester-induced macrophage differentiation in HL-60 leukemia cells without disappearance of protein kinase C. Leuk. Res. 10:1425-1432; 1986.
9. Yang, K. D.; Mizobuchi, T.; Kharbanda, S. M.; Datta, R.; Huberman, E.; Kufe, D. W.; Stone, R. M. All-trans retinoic acid reverses phorbol ester resistance in a human myeloid leukemia cell line. Blood 83:490-496; 1994.
10. Hansen, L. A.; Sigman, C. C.; Andreola, F.; Ross, S. A.; Kelloff, G. J.; De Luca, L. M. Retinoids in chemoprevention and differentiation therapy. Carcinogenesis 21:1271-1279; 2000.
11. Breitman, T. R.; Selonick, S. E.; Collins, S. J. Induction of differentiation of the human promyelocytic leukemia cell line (HL-60) by retinoic acid. Proc. Natl. Acad. Sci. USA 77:2936-2940; 1980.
12. Huang, M. E.; Ye, Y. C.; Chen, S. R.; Chai, J. R.; Lu, J. X.; Zhoa, L.; Gu, L. J.; Wang, Z. Y. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 72:567-572; 1988.
13. Slack, J. L.; Rusiniak, M. E. Current issues in the management of acute promyelocytic leukemia. Ann. Hematol. 79:227-238; 2000.
14. Issa, L. L.; Leong, G. M.; Eisman, J. A. Molecular mechanism of vitamin D receptor action. Inflamm. Res. 47:451-457; 1998.
15. 3-induced differentiation in human promyelocytic leukemia HL-60 cells. Oncol. Res. 9:19-29; 1997.
16. 3. Oncol. Res. 9:31-39; 1997.
17. Mawer, E. B.; Backhouse, J.; Davies, M.; Hill, L. F.; Taylor, C. M. Metabolic fate of administered 1,25-dihydroxycholecalciferol in controls and in patients with hypoparathyroidism. Lancet 1203-1206; 1976.
18. Holick, M. F. Vitamin D. In: Modern nutrition in health and disease. Baltimore: Williams & Wilkins; 1999:329-341.
19. Prasad, K. N. Butyric acid: A small fatty acid with diverse biological functions. Life Sci. 27:1351-1358; 1980.
20. Rephaeli, A.; Rabizadeh, E.; Aviram A.; Shaklai, M.; Ruse, M.; Nedelman, A. Derivatives of butyric acid as polential anti-neoplastic agents. Int. J. Cancer 49:66-72; 1991.
21. Egorin, M. J.; Yuan, Z. M.; Sentz, D. L.; Plaisance, K.; Eiseman, J. L. Plasma pharmacokinetics of butyrate after intravenous administration of sodium butyrate or oral administration of tributyrin or sodium butyrate to mice and rats. Cancer Chemother. Pharmacol. 43:445-453; 1999.
22. Miller, A. A.; Kurschel, E.; Osieka, R.; Schmidt, C. G. Clinical pharmacology of sodium butyrate in patients with acute leukemia. Eur. J. Cancer Clin. Oncol. 23:1283-1287; 1987.
23. Conley, B. A.; Egorin, M. J.; Tait, N.; Rosen, D. M.; Sausville, E. A.; Dover, G.; Fram, R. J.; van Echo, D. A. Phase I study of the orally administrated butyrate prodrug, tributyrin, in patients with solid tumors. Clin. Cancer Res. 4:629-634; 1998.
24. Warrell, R. P.; He, L. Z.; Richon, V.; Calleja, E.; Pandolfi, P. P. Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J. Natl. Cancer Inst. 90:1621-1625; 1998.
25. Collins, S. J. The HL-60 promyelocytic leukemia cell line: Proliferation, differentiation, and cellular oncogene expression. Blood 70:1233-1244; 1987.
26. Semizarov, D.; Glesne, D.; Laouar, A.; Schiebel, K.; Huberman, E. A lineage-specific protein kinase crucial for myeloid maturation. Proc. Natl. Acad. Sci. USA 95:15412-15417; 1998.
27. Berenbaum, M. C. What is synergy? Pharmacol. Rev. 41:93-141; 1989.
28. Laska, E. M.; Meisner, M.; Siegel, C. Simple designs and model-free tests for synergy. Biometrics 50:834-841; 1994.
29. Satterthwaite, F. W. An approximate distribution of estimates of variance components. Biometrics Bull. 2:110-114; 1946.
30. Chen, G. Q.; Shen, Z. X.; Wu, F.; Han, J. Y.; Miao, J. M.; Zhong, H. J.; Li, X. S.; Zhao, J. Q.; Zhu, J.; Fang, Z. W.; Chen, S. J.; Chen, Z.; Wang, Z. Y. Pharmacokinetics and efficacy of low-dose all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Leukemia 10:825-828; 1996.
31. Bouzinba-Segard, H.; Fan, X. T.; Perderiset, M.; Castagna, M. Synergy between phorbol esters and retinoic acid in inducing protein kinase C activation. Biochem. Biophys. Res. Commun. 204: 112-119; 1994.
32. 3 enhances cytosolic free calcium in HL-60 cells. Exp. Hematol. 18:1147-1151; 1990.
33. 3. J. Cell. Physiol. 172:284-295; 1997.
34. 2+ and phorbol ester synergistically induce HL-60 differentiation. FEBS Lett. 206:99-105; 1986.
35. Candido, E. P.; Reeves, R.; Davie, J. R. Sodium butyrate inhibits histone deacetylation in cultured cells. Cell 14:105-113; 1978.
36. Taimi, M.; Chen, Z. X.; Breitman, T. R. Potentiation of retinoic acid-induced differentiation of human acute promyelocytic leukemia NB4 cells by butyric acid, tributyrin, and hexamethylene bis-acetamide. Oncol. Res. 10:75-84; 1998.
37. Nedelman, A.; Rephaeli, A. Novel mutual prodrug of retinoic and butyric acids with enhanced anticancer activity. J. Med. Chem. 43:2962-2966; 2000.
38. Samid, D.; Hudgins, W. R.; Shack, S.; Liu, L.; Prasanna, P.; Myers, C. E. Phenylacetate and phenylbutyrate as novel, nontoxic differentiation inducers. Adv. Exp. Med. Biol. 400A:501-505; 1997.
39. Lea, M. A.; Randolph, V. M.; Hodge, S. K. Induction of histone acetylation and growth regulation in erythroleukemia cells by 4-phenylbutyrate and structural analogs. Anticancer Res. 19:1971-1976; 1999.
40. Chen, Z. X.; Breitman, T. R. Tributyrin: A prodrug of butyric acid for potential clinical application in differentiation therapy. Cancer Res. 54:3494-3499; 1994.
41. Nedelman, A.; Ruse, M.; Aviram, A.; Rabizadeh, E.; Shaklai, M.; Zimra, Y.; Rephaeli, A. Novel anticancer prodrugs of butyric acid. J. Med. Chem. 35:687-694; 1992.
42. Godyn, J. J.; Xu, H.; Zhang, F.; Kolla, S.; Studzinski, G. P. A dual block to cell cycle progression in HL60 cells exposed to analogues of vitamin D3. Cell Prolif. 27:37-46; 1994.
43. Danielsson, C.; Mathiasen, I. S.; James, S. Y.; Nayeri, S.; Bretting, C.; Hansen, C. M.; Colston, K. W.; Carlberg, C. Sensitive induction of apoptosis in breast cancer cells by a novel 1,25-dihydroxyvitamin D3 analogue shows relation to promoter selectivity. J. Cell. Biochem. 66:552-562; 1997.
44. Opolski, A.; Wietrzyk, J.; Chrobak, A.; Marcinkowska, E.; Wojdat, E.; Kutner, A.; Radzikowski, C. Antiproliferative activity in vitro of side-chain analogues of calcitriol against various human normal and cancer cell lines. Anticancer Res. 19:5217-5222; 1999.
45. Hansen, C. M.; Hamberg, K. J.; Binderup, E.; Binderup, L. Seocalcitol (EB 1089): A vitamin D analogue of anti-cancer potential. Background, design, synthesis, pre-clinical and clinical evaluation. Curr. Pharm. Des. 6:803-828; 2000.
46. Garzotto, M.; White-Jones, M.; Jiang, Y.; Ehleiter, D.; Liao, W. C.; Haimovitz-Friedman, A.; Fuks, Z.; Kolesnick, R. 12-O-tetradecanoylphorbol-13-acetate-induced apoptosis in LNCaP cells is mediated through ceramide synthase. Cancer Res. 58: 2260-2264; 1998.
47. Guilbaud, N. F.; Gas, N.; Dupont, M. A.; Valette, A. Effects of differentiation-inducing agents on maturation of human MCF-7 breast cancer cells. J. Cell. Physiol. 145:162-172; 1990.
48. Arita, Y.; O'Driscoll, K. R.; Weinstein, I. B. Growth inhibition of human melanoma-derived cells by 12-O-tetradecanoylphorbol-13-acetate. Int. J. Cancer 56:229-235; 1994.
49. Salge, U.; Kilian, P.; Neumann, K.; Elsasser, H-P.; Havemann, K.; Heidtmann, H-H. Differentiation capacity of human non-small-cell lung cancer cell lines after exposure to phorbol ester. Int. J. Cancer 45:1143-1150; 1990.
50. Rickard, K. L.; Gibson, P. R.; Young, G. P.; Phillips, W. A. Activation of protein kinase C augments buyrate-induced differentiation and turnover in human colonic epithelial cells in vitro. Carcinogenesis 20:977-984; 1999.